Furthermore, a clinical trial in progress is studying the safety and efficacy of capmatinib plus pembrolizumab vs. pembrolizumab alone in NSCLC with PD-L1 ≥ 50% (NCT04139317), which might be the confirmation of a new improvement to the only MET-TKI therapies in patients with MET alterations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.